UY31824A - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY31824A
UY31824A UY0001031824A UY31824A UY31824A UY 31824 A UY31824 A UY 31824A UY 0001031824 A UY0001031824 A UY 0001031824A UY 31824 A UY31824 A UY 31824A UY 31824 A UY31824 A UY 31824A
Authority
UY
Uruguay
Prior art keywords
new compounds
diseases
beneficial
compound
formula
Prior art date
Application number
UY0001031824A
Other languages
English (en)
Inventor
Alvaro Giuseppe
Marasco Agostino
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of UY31824A publication Critical patent/UY31824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

La invención proporciona un compuesto der fórmula (I) o una sal farmacéuticamente aceptable del mismo, en donde R es alquilo de 1-4 C útil en el tratamiento de enfermedades y afecciones para las que es beneficioso el antagonismo del receptor NK1
UY0001031824A 2008-05-14 2009-05-12 Nuevos compuestos UY31824A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0808747.0A GB0808747D0 (en) 2008-05-14 2008-05-14 Novel compounds

Publications (1)

Publication Number Publication Date
UY31824A true UY31824A (es) 2009-11-10

Family

ID=39571329

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031824A UY31824A (es) 2008-05-14 2009-05-12 Nuevos compuestos

Country Status (22)

Country Link
US (4) US8344005B2 (es)
EP (1) EP2300452B1 (es)
JP (1) JP5465716B2 (es)
KR (1) KR101567116B1 (es)
CN (1) CN102105458B (es)
AR (1) AR071721A1 (es)
AU (1) AU2009248102B8 (es)
BR (1) BRPI0911990B1 (es)
CA (1) CA2724219C (es)
CL (1) CL2009001146A1 (es)
DK (1) DK2300452T3 (es)
EA (1) EA019037B1 (es)
ES (1) ES2446866T3 (es)
GB (1) GB0808747D0 (es)
IL (1) IL209197A (es)
MX (1) MX2010012421A (es)
PE (1) PE20091847A1 (es)
PL (1) PL2300452T3 (es)
TW (1) TWI444376B (es)
UY (1) UY31824A (es)
WO (1) WO2009138393A1 (es)
ZA (1) ZA201007904B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
TWI649307B (zh) * 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
WO2018197638A1 (en) 2017-04-27 2018-11-01 Nerre Therapeutics Limited Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide
WO2021154631A1 (en) * 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders
CN115697332A (zh) * 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102490T2 (tr) 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
ATE496032T1 (de) 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
RS50932B (sr) 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
KR100599134B1 (ko) 2001-04-23 2006-07-12 에프. 호프만-라 로슈 아게 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP5121716B2 (ja) * 2005-09-09 2013-01-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ピリジン誘導体および精神異常の処置におけるそれらの使用
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators

Also Published As

Publication number Publication date
CL2009001146A1 (es) 2010-09-24
IL209197A0 (en) 2011-01-31
EA019037B1 (ru) 2013-12-30
BRPI0911990A2 (pt) 2020-08-18
TW201006813A (en) 2010-02-16
KR20110017384A (ko) 2011-02-21
EA201071299A1 (ru) 2011-06-30
US8344005B2 (en) 2013-01-01
CN102105458B (zh) 2013-06-12
US20090286836A1 (en) 2009-11-19
BRPI0911990B1 (pt) 2021-07-13
CA2724219C (en) 2016-04-05
PL2300452T3 (pl) 2014-04-30
JP5465716B2 (ja) 2014-04-09
CN102105458A (zh) 2011-06-22
AU2009248102A1 (en) 2009-11-19
DK2300452T3 (da) 2014-02-17
EP2300452B1 (en) 2013-11-20
WO2009138393A1 (en) 2009-11-19
JP2011520834A (ja) 2011-07-21
GB0808747D0 (en) 2008-06-18
MX2010012421A (es) 2011-03-25
US9006271B2 (en) 2015-04-14
US8822504B2 (en) 2014-09-02
US20130143931A1 (en) 2013-06-06
AU2009248102B8 (en) 2012-07-26
US20140249188A1 (en) 2014-09-04
EP2300452A1 (en) 2011-03-30
ZA201007904B (en) 2011-11-30
TWI444376B (zh) 2014-07-11
ES2446866T3 (es) 2014-03-10
PE20091847A1 (es) 2010-01-09
KR101567116B1 (ko) 2015-11-06
IL209197A (en) 2014-09-30
CA2724219A1 (en) 2009-11-19
AR071721A1 (es) 2010-07-07
US20110060015A1 (en) 2011-03-10
AU2009248102B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20140413A (es) Inhibidores de serina/treonina cinasa
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
UY32848A (es) Compuestos heterocíclicos de oxima
DOP2012000149A (es) Compuestos triciclicos novedosos
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
UY31824A (es) Nuevos compuestos
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
DOP2006000170A (es) Nuevos derivados de espirocromanona
ECSP088627A (es) Compuestos para el tratamiento de trastornos inflamatorios
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200528